Impact of Hormonal Therapy on Intermediate Risk Prostate Cancer Treated With Combination Brachytherapy and External Beam Irradiation

No AccessJournal of UrologyAdult Urology1 Feb 2010Impact of Hormonal Therapy on Intermediate Risk Prostate Cancer Treated With Combination Brachytherapy and External Beam Irradiationis corrected byErratum Richard G. Stock, Swati Yamalachi, Simon J. Hall, and Nelson N. Stone Richard G. StockRichard G. Stock , Swati YamalachiSwati Yamalachi , Simon J. HallSimon J. Hall , and Nelson N. StoneNelson N. Stone View All Author Informationhttps://doi.org/10.1016/j.juro.2009.10.006AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We assessed the impact of androgen suppressive therapy on biochemical failure in patients with intermediate risk prostate cancer treated with brachytherapy and external beam irradiation. Materials and Methods: From 1994 to 2006, 432 patients with intermediate risk prostate cancer as defined by the National Comprehensive Cancer Network were treated with low dose rate brachytherapy and external beam irradiation with or without 9 months of androgen suppressive therapy. Gleason score was 7 in 76% of cases and prostate specific antigen was 1.4 to 20 ng/ml (median 7.6). Of the patients 350 received androgen suppressive therapy and 82 did not. The biologically effective dose was 142 to 280 Gy2 (median 206). Followup was 23 to 155 months (median 56). Results: The overall 8-year biochemical failure-free rate using the Phoenix definition in patients with vs without androgen suppressive therapy was 92% vs 92% (p = 0.4). The therapy had no significant impact on the biochemical failure-free rate in patients with Gleason score 7 (92% vs 90.5%, p = 0.55), prostate specific antigen 10 to 20 ng/ml (92% vs 100%, p = 0.32), T2b-T2c disease (89.5% vs 97%, p = 0.27) and more than 1 intermediate risk feature (90% vs 100%, p = 0.2). Conclusions: We addressed the relative importance of radiation dose vs hormonal therapy for intermediate risk prostate cancer. With high biologically effective dose combination treatment androgen suppressive therapy did not have a significant impact on the 8-year biochemical failure-free rate. We question its routine use in this setting. References 1 : Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet2002; 360: 103. Google Scholar 2 : Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomized controlled trial. Lancet Oncol2005; 6: 841. Google Scholar 3 : Phase III Radiation Therapy Oncology group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Boil Phys2001; 50: 1243. Google Scholar 4 : Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long term results of Phase III RTOG 85-31. Int J Radiat Oncol Biol Phys2005; 61: 1285. Google Scholar 5 : 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. JAMA2004; 292: 821. Google Scholar 6 : Biologically effective dose values for prostate brachytherapy: effects on PSA failure and post treatment biopsy results. Int J Radiat Oncol Biol Phys2006; 64: 527. Google Scholar 7 : Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys2004; 59: 1352. Google Scholar 8 : Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys2008; 70: 67. Google Scholar 9 : Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys2007; 69: 1472. Google Scholar 10 : A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys1995; 32: 219. Google Scholar 11 : Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer; recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys2006; 65: 965. Google Scholar 12 : SPSS 10.0 Guide to Data Analysis. : 2000. Upper Saddle River: Prentice-Hall. Google Scholar 13 : Sexual potency following interactive ultrasound guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys1996; 35: 267. Google Scholar 14 : Examining the role of neoadjuvant deprivation in patients undergoing prostate brachytherapy. J Clin Oncol2000; 18: 1187. Google Scholar 15 : The impact of hormone therapy on post-implant dosimetry and outcome following I-125 implant monotherapy for localized prostate cancer. Radiother Oncol2005; 75: 303. Google Scholar 16 : Role of hormonal therapy in the management of intermediate to high risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys2002; 52: 444. Google Scholar 17 : Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer2007; 110: 551. Google Scholar 18 : Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk features?. BJU Int2003; 91: 23. Google Scholar 19 : No apparent benefit at 5 years from a course of neoadjuvant/concurrent androgen deprivation for patients with prostate cancer treated with high total radiation dose. J Urol2003; 170: 2296. Link, Google Scholar Departments of Radiation Oncology and Urology, Mount Sinai School of Medicine, New York, New York© 2010 by American Urological AssociationFiguresReferencesRelatedDetailsCited byTaneja S (2020) Re: Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men with Locally Advanced Prostate Cancer: 10-Year Data from the TROG 03.04 RADAR TrialJournal of Urology, VOL. 204, NO. 4, (879-880), Online publication date: 1-Oct-2020.Related articlesJournal of Urology24 Feb 2010Erratum Volume 183Issue 2February 2010Page: 546-551 Advertisement Copyright & Permissions© 2010 by American Urological AssociationKeywordsandrogen antagonistsradiotherapyprostateprostatic neoplasmsbrachytherapyMetricsAuthor Information Richard G. Stock More articles by this author Swati Yamalachi More articles by this author Simon J. Hall More articles by this author Nelson N. Stone Financial interest and/or other relationship with Prologics, Nihon-MediPhysics, IsoAid and Prostate Cancer Educational Council. More articles by this author Expand All Advertisement PDF downloadLoading ...